Related Experiment Video
Updated: May 30, 2026
09:43
Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells
Published on: March 8, 2024
[Non-cytokine therapeutic targets].
José Federico Díaz González1, Sagrario Bustabad Reyes
1Servicio de Reumatología, Hospital Universitario de Canarias, Tenerife, España.
Reumatologia Clinica
|July 29, 2011
Summary
Anti-tumor necrosis factor-alpha (TNF-α) therapies are effective but not for all rheumatoid arthritis (RA) patients. New biologics targeting B cells, T cells, and signal transduction pathways offer improved treatment options for RA.
Area of Science:
- Rheumatology and immunology
- Translational research in drug development
Context:
- Anti-tumor necrosis factor-alpha (TNF-α) therapies represent a significant advancement in rheumatoid arthritis (RA) treatment.
- However, a substantial portion of RA patients do not achieve clinical remission with anti-TNF-α agents.
Purpose:
- To review the evolution of biologic and small molecule therapies for rheumatoid arthritis (RA).
- To discuss the efficacy and limitations of current treatments and emerging therapeutic strategies targeting novel pathways.
Summary:
- Biological drugs targeting non-cytokine pathways, such as B-cell depletion and T-cell activation interference, have demonstrated efficacy in managing RA signs, symptoms, and structural damage.
- Second-generation B-cell therapies aim to improve upon existing treatments like rituximab, though significant improvements in remission rates are not anticipated.
- Small molecule inhibitors targeting signal transduction pathways, particularly Jak3 and Syk inhibitors, represent a promising new frontier in anti-inflammatory drug research for rheumatic diseases, outperforming earlier p38 MAPK inhibitors.
Impact:
- Highlights the limitations of current anti-TNF-α therapies and the need for alternative treatments in rheumatoid arthritis.
- Underscores the potential of novel biological and small molecule drugs targeting distinct pathways for improved RA management.
- Provides insight into the future direction of drug discovery for inflammatory rheumatic diseases, emphasizing signal transduction modulation.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...